Skip to main content
SpringerLink
Log in

Behandlung des hyperkinetischen Herzsyndroms mit Alinidine und Propranolol

Alinidine and propranolol treatment of hyperkinetic heart syndrome

  • Originalien
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Summary

A hyperkinetic heart syndrome has been diagnosed in 10 patients by clinical investigation and right-heart catheterization at rest and during exercise. Subsequently, the patients received 3×40 mg alinidine, and 2×40 mg propranolol and placebo, each for 2 weeks in a double-blind cross-over study.

Heart rate at rest (P<0.05) and during exercise (P<0.001) decreased significantly under alinidine and propranolol to the same extent (control, 83/170; alinidine, 68/146; propranolol, 73/139; placebo, 83/162 beats per min). Lower limb flow at rest and after exercise, measured by plethysmography, as well as left-ventricular fractional shortening and mean velocity of circumferential fiber shortening, measured by echocardiography, decreased insignificantly.

Sedation and a dry mouth occurred in six patients under alinidine, while fatigue and cold hands and/or feet were reported by five patients under propranolol. Thus, alinidine may be used as an alternative to beta-blocking in the treatment of the hyperkinetic heart syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

A:

Behandlung mit Alinidine

B:

Behandlung mit Propranolol

B1–B6 :

Belastungsminuten

E1–E5 :

Erholungsminuten

FS%:

prozentuale linksventrikuläre Verkürzungsfraktion

HF:

Herzfrequenz

K:

Kontrolluntersuchung

Li:

Liegen

LVEDD:

linksventrikulärer enddiastolischer Durchmesser

LVESD:

linksventrikulärer endsystolischer Durchmesser

P:

Behandlung mit Placebo

St:

Stehen

TM-Mode:

time-motion-mode

Vcf:

mittlere zirkumferentielle Faserverkürzungsgeschwindigkeit

Literatur

  1. Arndts D, Forster HJ (1981) New aspects in the metabolism of alinidine in man. Eur J Drug Metab Pharmakokin 6:313–315

    Google Scholar 

  2. Bollinger A, Gander M, Forster G (1965) Pulsfrequenz und Leistungsfähigkeit vor und nachβ-Rezeptoren-Blockade durch Propranolol. Schweiz Med Wochenschr 95:1075–1079

    Google Scholar 

  3. Bollinger A, Gander M, Pylkkänen, Forster G (1966) Treatment of the hyperkinetic heart syndrome with propranolol. Cardiologia 49 (Suppl 2):68–82

    Google Scholar 

  4. Bollinger A, Simon HJ (1976) Einfluß adrenergischerβ-Rezeptoren-Blockade auf die Unterarmdurchblutung bei Patienten mit hyperkinetischem Herzsyndrom und vegetativer Ruhetachykardie. Dtsch Med Wochenschr 92:28–30

    Google Scholar 

  5. Bollinger A (1969) Durchblutungsmessungen in der klinischen Angiologie, mit besonderer Berücksichtigung der Venenverschluß-Plethysmographie. Series Angiologica, Band IV, Huber, Bern

  6. Brachfeld N, Gorlin R (1960) Idiopathic hyperkinetic state: a new clinical syndrome. Br Heart J 22:353–360

    Google Scholar 

  7. Delius L (1972) Funktionelle kardiovaskuläre Störungen. Internist 13:1–6

    Google Scholar 

  8. Fiorentini C, Olivari MT, Moruzzi P, Guazzi MD (1981) Long-term follow up of the primary hyperkinetic heart syndrome. An echocardiographic and hemodynamic study. Am J Med 71:221–227

    Google Scholar 

  9. Frohlich ED (1971) Beta adrenergic blockade in the circulatory regulation of hyperkinetic states. Am J Cardiol 27:195–199

    Google Scholar 

  10. Gillium RF, Teichholz LE, Herman MW, Gorlin R (1981) The idiopathic hyperkinetic heart syndrome: clinical course and long-term prognosis. Am Heart J 102:728–734

    Google Scholar 

  11. Gorlin R, Brachfeld N, Turner JD, Messer JV, Salazar E (1959) The idiopathic high cardiac output state. J Clin Invest 38:2144–2153

    Google Scholar 

  12. Gorlin R (1962) The hyperkinetic heart syndrome. J Am Med Assoc 182:823–829

    Google Scholar 

  13. Guazzi M, Polese A, Magrini F, Fiorentini C, Olivari MT (1975) Long-term treatment of the hyperkinetic heart syndrome with propranolol. Am J Med Sci 270:465–474

    Google Scholar 

  14. Harron DWG, Riddel JG, Shanks RG (1981) Cardiovascular effects of alinidine (ST 567) in healthy volunteers. Br J Clin Pharmacol 11:116–117

    Google Scholar 

  15. Harron DWG, Shanks RG, Riddel JG (1981) Alinidine reduces heart-rate without blockade of beta adrenoceptors. Lancet 1, 1981:351–353

    Google Scholar 

  16. Harron DWG, Jady K, Riddel JG, Shanks RG (1982) Effects of alinidine, a novel bradycardic agent, on heart rate and blood pressure in man. J Cardiovasc Pharmacol 4:213–220

    Google Scholar 

  17. Harron DWG, Arndts D, Shanks RG (1982) Alinidine pharmakokinetics following acute and chronic dosing. Br J Clin Pharmacol 13:821–827

    Google Scholar 

  18. Harron DWG, Arndts D, Finck M, Shanks RG (1983) An assessment of the contribution of clonidine metabolised from alinidine to the cardiovascular effects of alinidine. Br J Clin Pharmacol 16:451–455

    Google Scholar 

  19. Henry WL, Ware J, Gardin JM, Hepner SJ, McKay J, Weisner M (1978): Echocardiographic measurement in normal subjects: growth related changes that occur between infancy and early adulthood. Circulation 57:278–285

    Google Scholar 

  20. Holmgren A, Jonsson B. Levander M, Lindesholm H, Sjöstrand T, Ström G (1957) Low physical working capacity in suspected heart cases due to inadequate adjustment of peripheral blood flow (vasoregulatory asthenia). Acta Med Scand 163:413–421

    Google Scholar 

  21. Juchems R, Wertz U (1969) Zentrale Hämodynamik des hyperkinetischen Syndroms unter Betarezeptorenblockade. Münch Med Wochenschr 111:2567–2571

    Google Scholar 

  22. Kaltenbach M, Becker HJ, Brunn V (1968) Beeinflussung der körperlichen Leistungsfähigkeit und der Muskeldurchblutung durch Beta-Receptorenblocker bei hyperkinetischer Kreislaufregulationsstörung. Verh Dtsch Ges Inn Med 74:565–568

    Google Scholar 

  23. Kaltenbach M (1974) Die Belastungs-Untersuchung von Herzkranken. Studienreihe Boehringer Mannheim

  24. Kobinger W, Lillie C (1984) Alinidine. In: Scriabine A (Hrsg) New drugs annual: cardiovascular drugs Vol. 2, Raven Press, New York, pp 193–210

    Google Scholar 

  25. Lohmöller G, Albrecht A, Lydtin H (1970) Plethysmographische Untersuchungen über die Wirkung derβ-Receptorenblocker Propranolol und Practolol auf die Unterschenkeldurchblutung bei Gesunden und Patienten mit hyperkinetischem Herzsyndrom. Verh Dtsch Ges Inn Med 76:927–930

    Google Scholar 

  26. Lydtin H, Schnelle K, Lohmöller G, Kusus T (1969) Über Diagnose und Therapie des hyperkinetischen Herzsyndroms. Verh Dtsch Ges Inn Med 75:402–405

    Google Scholar 

  27. Lydtin H (1974) Das hyperkinetische Herzsyndrom. Therapiewoche 20:2274–2278

    Google Scholar 

  28. Magometschnigg (1981) Das hyperkinetische Herzsyndrom. Hämodynamische und pathologische Untersuchungen bei Anwendung pharmakologischer und therapeutischer Maßnahmen. Angiocardiology 3:244–261

    Google Scholar 

  29. Sachs L (1983) Angewandte Statistik, 6. Auflage, Springer, Berlin Heidelberg New York

    Google Scholar 

  30. Siegl PKS, Wenger HC, Sweet CS (1984) Comparison of cardiovascular responses to the bradycardic drugs, alinidine, AQ-A 39, an mixidine, in the anesthetized dog. J Cardiovasc Pharmacol 6:565–574

    Google Scholar 

  31. Simoons ML, Hugenholtz PG (1984) Haemodynamic effects of alinidine, a specific sinus node inhibitor, in patients with unstable angina or myocardial infarction. Eur Heart J 5:227–232

    Google Scholar 

  32. Stanek B, Reiterer W, Placheta P, Raberger G (1983) Acute effects of alinidine on heart rate and blood pressure in healthy subjects and patients with hyperkinetic heart syndrome. Eur J Clin Pharmacol 24:31–34

    Google Scholar 

  33. Wiegand VW, Meinertz T, Kasper W, Jähnchen E (1981) Determination of alinidine in human plasma by high-performance liquid chromatography. Chromatogr 223:238–242

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung für Kardiologie und Abteilung für Angiologie Zentrum der Inneren Medizin, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt am Main, Germany

    R. Schräder, G. Degoutrie, H. Landgraf & M. Kaltenbach

Authors
  1. R. Schräder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Degoutrie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Landgraf
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Kaltenbach
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Die Arbeit enthält Teile der Dissertation von G. Degoutrie

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schräder, R., Degoutrie, G., Landgraf, H. et al. Behandlung des hyperkinetischen Herzsyndroms mit Alinidine und Propranolol. Klin Wochenschr 65, 69–75 (1987). https://doi.org/10.1007/BF01745476

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01745476

Key words

Search

Navigation